Serina Therapeutics Statistics
Total Valuation
SER has a market cap or net worth of $22.98 million. The enterprise value is $26.95 million.
| Market Cap | 22.98M |
| Enterprise Value | 26.95M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SER has 2.50 million shares outstanding.
| Shares Outstanding | 2.50M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -0.03% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 161.86 |
| Forward PS | n/a |
| PB Ratio | 4.20 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 189.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.13, with a Debt / Equity ratio of 0.80.
| Current Ratio | 0.13 |
| Quick Ratio | 0.08 |
| Debt / Equity | 0.80 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -120.90% |
| Return on Capital (ROIC) | -100.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -59.36% in the last 52 weeks.
| Beta (1Y) | n/a |
| 52-Week Price Change | -59.36% |
| 50-Day Moving Average | 12.83 |
| 200-Day Moving Average | 18.78 |
| Relative Strength Index (RSI) | 37.03 |
| Average Volume (30 Days) | 5,145 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SER had revenue of $142,000 and -$14.80 million in losses. Loss per share was -$13.72.
| Revenue | 142,000 |
| Gross Profit | 102,000 |
| Operating Income | -9.88M |
| Pretax Income | -14.80M |
| Net Income | -14.80M |
| EBITDA | -9.77M |
| EBIT | -9.90M |
| Loss Per Share | -$13.72 |
Balance Sheet
The company has $395,000 in cash and $4.37 million in debt, giving a net cash position of -$3.97 million or -$1.59 per share.
| Cash & Cash Equivalents | 395,000 |
| Total Debt | 4.37M |
| Net Cash | -3.97M |
| Net Cash Per Share | -$1.59 |
| Equity / Book Value | 5.47M |
| Book Value Per Share | 2.19 |
| Working Capital | -5.16M |
Cash Flow
| Operating Cash Flow | -7.80M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.80M |
| FCF Per Share | -$7.23 |
Margins
Gross margin is 71.83%, with operating and profit margins of -6,954.93% and -10,424.65%.
| Gross Margin | 71.83% |
| Operating Margin | -6,954.93% |
| Pretax Margin | -10,424.65% |
| Profit Margin | -10,424.65% |
| EBITDA Margin | -6,881.69% |
| EBIT Margin | -6,973.94% |
| FCF Margin | -5,492.96% |
Dividends & Yields
SER does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -64.41% |
| FCF Yield | -33.94% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SER has an Altman Z-Score of -16.48 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -16.48 |
| Piotroski F-Score | 3 |